Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01567982 · ClinicalTrials.gov registry record · Phase 1
Effects of Transcranial Direct Current Stimulation on Tobacco Withdrawal Symptoms
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01567982 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 60 participants.
The verdict
NCT01567982, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
We hypothesize that transcranial direct current stimulation will reduce tobacco withdrawal symptoms of tobacco dependent smokers abstinent from smoking for more than 10 hours.
Interventions
- DEVICE tDCS, prefrontal cortex and parietal cortex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01567982
The ClinicalTrials.gov registry entry for NCT01567982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tDCS, prefrontal cortex and parietal cortex is the first listed.
NCT01567982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01567982 about?
NCT01567982 is a clinical study titled "Effects of Transcranial Direct Current Stimulation on Tobacco Withdrawal Symptoms". We hypothesize that transcranial direct current stimulation will reduce tobacco withdrawal symptoms of tobacco dependent smokers abstinent from smoking for more than 10 hours.
What is the current status of trial NCT01567982?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01567982?
The interventions under investigation include: tDCS, prefrontal cortex and parietal cortex (DEVICE).
Who is sponsoring clinical trial NCT01567982?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.